CorneaGen
  • SURGEON PORTAL
  • Contact Us
  • CORNEAL TISSUE
    • Tissue Overview
    • Tissue Services
      • DSAEK
      • DMEK
      • Pre-Loaded DMEK
      • Ampho B
      • PKP
      • ALK
      • BrightMEM
      • FLAK
      • Non-Sterile Sclera
    • Tissue Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
    • Request Tissue
  • Sterile Tissue
    • CTAK
    • VisionGraft
      • Glaucoma
      • Cornea
    • Sclera
    • Reimbursement
      • CTAK Reimbursement
      • VisionGraft Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
  • CTAK
    • CTAK Overview
    • CTAK International
    • CTAK Reimbursement
  • Products
    • Products Overview
    • EndoSerter-PL
    • EndoSerter
    • Cannula
    • DescePro System
    • Donor Punch
    • Recipient Trephine
  • Education
    • Educational Videos
    • Wet Labs
    • Fellows Program
  • About Us
    • Our People
    • Our Partners
    • Our Locations
    • Reimbursement
    • Gift of Sight
    • News & Events
    • Core Commitments
    • Innovation
    • Careers
Request Tissue Contact Us
Patrick Lally

Patrick Lally

April 12, 2022

Patrick Lally is a partner at Petrichor Healthcare Capital Management, a life sciences-focused investment firm. Prior to joining Petrichor, Mr. Lally was a vice president at OrbiMed Advisors in their healthcare special situations and structured finance practice. Before OrbiMed, Mr. Lally was a healthcare investor in the Drawbridge Special Opportunities Fund at Fortress Investment Group. Mr. Lally holds an M.B.A. from The Wharton School at the University of Pennsylvania and an A.B. in Molecular Biology from Princeton University.

Recent Articles

  • CEO Update – June 2025

    CEO Update – June 2025

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • Bernie’s Quarterly Update – November 2024

    Bernie’s Quarterly Update – November 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • Bernie’s Quarterly Update – July 2024

    Bernie’s Quarterly Update – July 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes Advanced...

    READ MORE
Navigation
  • Corneal Tissue
  • Sterile Tissue
  • CTAK
  • Products
  • Education
  • About Us
  • Request Tissue
Helpful Information
  • Reimbursement assistance
  • Adverse reaction reporting
  • Regulatory Information
  • KAMRA Support
  • Careers
Legal
  • Privacy Policy
  • Proprietary Terms and conditions
  • Regulatory Information
  • Vendor Information
  • Billing Terms and Conditions
  • Purchase Order Terms and Conditions
Connect
  • Contact Us
CorneaGen

©2025 CorneaGen

CorneaGen